Shamsadini Sadollah, Fekri Alireya R, Esfandiarpoor Iraj, Saryazdi Simin, Rahnama Zahra, Zandi Soodabeh, Farajzadeh Saeideh
Department of Dermatology, Kerman University of Medical Sciences, Kerman, Iran.
Int J Dermatol. 2006 Jun;45(6):668-71. doi: 10.1111/j.1365-4632.2005.02614.x.
Pemphigus has in the past been associated with a high mortality rate. However, with the discovery of corticosteroids, patient median survival has improved. Our purpose was to assess median survival after confirmed diagnosis of pemphigus in patients in Kerman, a southern province of Iran.
All patients who were either admitted to the hospital or treated as outpatients in Kerman from 22 September 1987 to 22 September 1999 and who had confirmed pemphigus were included in the study. Survival was estimated using the Kaplan-Meier method, and the following variables were evaluated in a univariate analysis for an association with survival: age, sex, type of pemphigus, and type of therapy.
A total of 55 patients (38 female and 17 male) were identified. No significant differences were found between genders. The mean age at the time of diagnosis was 46.0 years. Older groups had a lower survival rate than younger groups (P < 0.001). The majority (82%) of cases were vulgaris/vegetans, and no significant differences were found in 10-year survival for type of pemphigus (P > 0.05). The patients who had been treated with corticosteroids alone had longer median survival times than those who had been treated with corticosteroids plus azathioprine (P < 0.001). A total of 11 patients died; the median follow-up time for those still alive was 5.9 years (range 2-12 years). Estimated survival at 2, 6 and 10 years was 92.7, 86.8 and 61.5%, respectively.
Overall median survival rate in patients with pemphigus was 10 years, regardless of gender or subtype of pemphigus. Survival was adversely affected by late onset. Those patients treated with immunosuppressives and corticosteroids also appeared to have reduced survival times when compared to those treated with corticosteroids alone.
过去,天疱疮的死亡率很高。然而,随着皮质类固醇的发现,患者的中位生存期有所改善。我们的目的是评估伊朗南部克尔曼省确诊天疱疮患者的中位生存期。
纳入1987年9月22日至1999年9月22日期间在克尔曼住院或门诊治疗且确诊为天疱疮的所有患者。采用Kaplan-Meier法估计生存率,并在单因素分析中评估以下变量与生存率的相关性:年龄、性别、天疱疮类型和治疗类型。
共确定55例患者(38例女性和17例男性)。性别之间未发现显著差异。诊断时的平均年龄为46.0岁。老年组的生存率低于年轻组(P<0.001)。大多数病例(82%)为寻常型/增殖型,天疱疮类型的10年生存率未发现显著差异(P>0.05)。仅接受皮质类固醇治疗的患者中位生存期比接受皮质类固醇加硫唑嘌呤治疗的患者长(P<0.001)。共有11例患者死亡;仍存活患者的中位随访时间为5.9年(范围2 - 12年)。2年、6年和10年的估计生存率分别为92.7%、86.8%和61.5%。
无论性别或天疱疮亚型如何,天疱疮患者的总体中位生存期为10年。发病较晚对生存有不利影响。与仅接受皮质类固醇治疗的患者相比,接受免疫抑制剂和皮质类固醇治疗的患者似乎生存期也缩短。